Medicus Pharma (MDCX) Chief Scientific Officer awarded 25,000 options at $0.36

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported that Chief Scientific Officer Brennan Edward J. received a grant of stock options. The award covers 25,000 options for Common Shares at an exercise price of $0.36 per share. According to the footnote, the options vest quarterly in four equal installments over one year and expire on June 3, 2031.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brennan Edward J.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 25,000 options Exercise price: $0.36 per share Total options after grant: 25,000 options +3 more

6 metrics

Options granted 25,000 options Stock Option (right to buy) grant to CSO

Exercise price $0.36 per share Conversion or exercise price for options

Total options after grant 25,000 options Total derivative securities following transaction

Grant date June 3, 2026 Option grant date in footnote

Expiration date June 3, 2031 Option expiration date

Vesting schedule 4 quarterly installments over 1 year Footnote description of vesting

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.3600" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"scheduled to vest quarterly in four equal installments over one year"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2031-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brennan Edward J.

(Last)

(First)

(Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W.CONSHOHOCKEN

PENNSYLVANIA

19428

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.36	06/03/2026		A		25,000		⁽¹⁾	06/03/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Edward J. Brennan	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Medicus Pharma (MDCX) disclose in this Form 4 filing?

Medicus Pharma disclosed that its Chief Scientific Officer, Brennan Edward J., received a grant of 25,000 stock options. These options are part of his compensation and give him the right to buy Common Shares at a fixed exercise price.

How many stock options were granted to the Medicus Pharma (MDCX) CSO?

The Chief Scientific Officer was granted 25,000 stock options. Each option relates to one Common Share, providing potential future ownership if exercised at the stated $0.36 per-share exercise price before the expiration date.

What is the exercise price of the new Medicus Pharma (MDCX) options?

The granted options have an exercise price of $0.36 per share. This means the holder can later purchase Medicus Pharma Common Shares at $0.36, regardless of the market price at the time of exercise, if the options are vested and unexpired.

When do Brennan Edward J.’s Medicus Pharma (MDCX) options vest?

The options are scheduled to vest quarterly in four equal installments over one year. This structure gradually makes portions of the 25,000 options exercisable, aligning vesting with continued service through the one-year vesting period.

When do the newly granted Medicus Pharma (MDCX) options expire?

The options expire on June 3, 2031. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Medicus Pharma Common Shares at the $0.36 exercise price described in the filing.

Did the Medicus Pharma (MDCX) CSO buy or sell shares in this Form 4?

The Form 4 shows an acquisition through a grant of stock options, not a market purchase or sale of shares. It records a compensation award of 25,000 options, rather than an open-market trade in existing Common Shares.